|
1) Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005; 42: 1208-36
|
|
|
|
2) Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007; 4: 424-32
|
|
|
|
|
|
3) Freeman RB, Mithoefer A, Ruthazer R, et al. Optimizing staging for hepatocellular cancer before liver transplantation. Liver Transpl. 2006; 12: 1504-11
|
|
|
|
|
|
4) Shah SA, Tan JC, McGilvray ID, et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation. 2006; 81: 1633-9
|
|
|
|
|
|
5) Leung JY, Zhu AX, Gordon FD, et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl. 2004; 10: 1343-54
|
|
|
|
|
|
6) Onaca N, Davis GL, Goldstein RM, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Liver Transpl. 2007; 13: 391-9
|
|
|
|
|
|
7) Decaens T, Roudot-Thoraval F, Hadni-Bresson S, et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 2006; 12: 1761-9
|
|
|
|
|
|
8) Grasso A, Stigliano R, Morisco F, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation. 2006; 81: 1532-41
|
|
|
|
|
|
9) Llovet JM. Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl. 2006; 12: 1741-3
|
|
|
|
|
|
10) Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005; 25: 181-200
|
|
|
|
|
|
11) Todo S, Furukawa H. Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg. 2004; 240: 451-9
|
|
|
|
|
|
12) Takada Y, Ueda M, Ito T, et al. Living donor liver transplantation as a second-line therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl. 2006; 12: 912-9
|
|
|
|
|
|
13) Soejima Y, Taketomi A, Yoshizumi T, et al. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation. 2007; 83: 893-9
|
|
|
|
|
|
14) Jonas S, Mittler J, Pascher A, et al. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl. 2007; 13: 896-903
|
|
|
|
|
|
15) Malago M, Sotiropoulos GC, Nadalin S, et al. Living donor liver transplantation for hepatocellular carcinoma: a single-center preliminary report. Liver Transpl. 2006; 12: 934-40
|
|
|
|
|
|
16) Gondolesi GE, Roayaie S, Munoz L, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg. 2004; 239: 142-9
|
|
|
|
|
|
17) Fisher RA, Kulik LM, Freise CE, et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant. 2007; 7: 1601-8
|
|
|
|
|
|
18) Freeman RB Jr. Transplantation for hepatocellular carcinoma: the Milan criteria and beyond. Liver Transpl. 2006; 12: S8-13
|
|
|
|
|
|
19) Cillo U, Vitale A, Grigoletto F, et al. Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria. Am J Transplant. 2007; 7: 972-81
|
|
|
|
|
|
20) Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant. 2005; 5: 795-804
|
|
|
|
|
|
21) Yao FY, Hirose R, LaBerge JM, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl. 2005; 11: 1505-14
|
|
|
|
|
|
22) Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006; 12: 1260-7
|
|
|
|
|
|
23) Porrett PM, Peterman H, Rosen M, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl. 2006; 12: 665-73
|
|
|
|
|
|
24) Lesurtel M, Mullhaupt B, Pestalozzi BC, et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis. Am J Transplant. 2006; 6: 2644-50
|
|
|
|
|
|
25) Zavaglia C, De Carlis L, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol. 2005; 100: 2708-16
|
|
|
|
|
|
26) Pawlik TM, Gleisner AL, Anders RA, et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg. 2007; 245: 435-42
|
|
|
|
|
|
27) Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg. 2004; 239: 150-9
|
|
|
|
|
|
28) Sutcliffe R, Maguire D, Portmann B, et al. Selection of patients with hepatocellular carcinoma for liver transplantation. Br J Surg. 2006; 93: 11-8
|
|
|
|
|
|
29) Ramos E, Llado L, Serrano T, et al. Utility of cell-cycle modulators to predict vascular invasion and recurrence after surgical treatment of hepatocellular carcinoma. Transplantation. 2006; 82: 753-8
|
|
|
|
|
|
30) Lin WY, Tsai SC, Hung GU. Value of delayed 18F-FDG-PET imaging in the detection of hepatocellular carcinoma. Nucl Med Commun. 2005; 26: 315-21
|
|
|
|
|
|
31) Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol. 2004; 39: 961-8
|
|
|
|
|
32) Yang SH, Suh KS, Lee HW, et al. The role of 18F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl. 2006; 12: 1655-60
|
|
|
|
|